Bacteroides dorei as Next Generation Probiotics
Background B. dorei and Disease Highlights Products FAQs Resources
It is increasingly recognized that Bacteroides dorei (B. dorei) plays a pivotal role in the development of several kinds of diseases such as cardiovascular disease and metabolic disease. Creative Biolabs has rich experience in developing and producing live biotherapeutic products, with both aerobic and anaerobic organisms. We now provide customized B. dorei-based drug discovery services and products for global clients. Our commercial products are strains of B. dorei which have been originally isolated from healthy human donors. They are grown in our cGMP-certified facility, encapsulated, and delivered selectively to the gut where they exert their therapeutic effects. Each strain is selected for its functionality in a similar way to how a small-molecule or biologic is selected to perform a specific role in combating a disease.
B. dorei Introduction
B. dorei is a species of bacteria within the genus Bacteroides. It is a gram negative, rod-shaped bacterium that contributes to normal intestinal functionality for humans and animals. B. dorei was isolated and differentiated from Bacteroides vulgatus (B. vulgatus) by using 16S rRNA sequencing and phenotypic tests in 2006. Research is being conducted to better understand the relationship B. dorei has on the human intestinal system and the autoimmune disease, type 1 diabetes (T1D).
B. dorei and Disease
Cardiovascular Disease
-
B. dorei is known to participate in the development of atherosclerotic cardiovascular disease. Analysis of gut microbial profile in patients with coronary artery disease (CAD) shows a relative depletion of B. vulgatus and B. dorei compared with controls without CAD with coronary risk factors. Gavage with live B. dorei decreases fecal and plasma lipopolysaccharide levels and protects against atherosclerosis in apolipoprotein E-deficient mice. Studies suggest that B. dorei treatment may serve as a novel and attractive therapeutic strategy for suppressing lipopolysaccharide-induced inflammatory response in CAD.
-
The microbial community in the human colon contains bacteria that reduce cholesterol to coprostanol. Strain D8 was isolated from a 10-8 dilution of a fresh stool sample provided by a senior male volunteer with a high capacity to convert cholesterol to coprostanol. B. dorei D8 has been shown to reduce luminal cholesterol to coprostanol in vitro and may be considered as a probiotic in the context of the cholesterol-cardiovascular-disease axis.
Fig.1 Chemical structures of cholesterol and coprostanol.1
Metabolic Disease
Besides the well-known direct effects of microbiota on the immune system, there are also indirect ways to affect autoimmunity, first and foremost the molecular mimicry process. In this perspective, there is long-time evidence about gut alterations leading to the development of T1D. Finally, studies revealed that B. dorei seems to dominate the gut microbiome in children at high risk for T1D.
Cancer
The tumor-specific Thomsen-Friedenreich antigen (TFα) is an attractive target for TFα-positive cancer treatment. A strain of B. ovatus, when fed to mice, increased levels of anti-TFα immunoglobulin (Ig) M (IgM) and IgG antibodies. Thus, this specific strain is a promising candidate for the development of the adjuvant-free anti-TFα-specific cancer vaccine.
Highlights of Our Bacteroides dorei Drug Discovery Services
-
Master and working cell bank preparation, validation, and storage
-
Fermentation and subsequent downstream purification
-
Downstream processing optimization and development
-
Multiple feed strategies and media options
-
Lyophilization or spray drying
The development of B. dorei-based live biotherapeutics offers a new way to create safe, effective, and convenient treatments for patients, presenting an opportunity to treat diseases that existing therapies are unable to effectively address. If you are interested in our services and products, please feel free to contact us for more information.
Related Products
|
CAT
|
Product Name
|
Product Overview
|
|
LBST-032FG
|
Bacteroides dorei
|
Bacteroides dorei was isolated from human feces. It is an Gram-negative, rod-shaped bacteria that contributes to normal intestinal functionality.
|
FAQs
Why is B. dorei considered important for gut health research?
Research has highlighted B. dorei's pivotal role in maintaining gut microbiome balance, which is crucial for digestive health and the immune system. It has been associated with reducing inflammation and the risk of certain diseases, making it a focal point for studies looking to leverage gut microbiota for overall health improvement. Its unique properties offer promising avenues for developing targeted probiotic therapies.
What services related to B. dorei probiotic discovery do you offer for researchers?
We offer a comprehensive suite of services for B. dorei probiotic discovery aimed at research and development teams. These services include genomic analysis to identify probiotic strains with desirable health benefits, in vitro and in vivo efficacy testing, and formulation development. These services are designed to accelerate the discovery and characterization of B. dorei strains with potential therapeutic applications.
What are the potential health benefits of researching B. dorei?
Research into B. dorei holds the promise of uncovering novel probiotic therapies for a range of conditions. Early studies suggest its potential in reducing inflammation, combating obesity, and even improving mental health by influencing the gut-brain axis. By understanding the specific mechanisms through which B. dorei interacts with the human microbiome, researchers can develop targeted interventions for a variety of health issues.
Can B. dorei products be used for diagnostic or therapeutic purposes?
Currently, B. dorei products and strains provided are strictly for research use only and are not approved for diagnostic or therapeutic purposes. Researchers are encouraged to explore the therapeutic potential of these probiotics within the scope of controlled studies to better understand their effects and mechanisms of action in various health contexts.
Resources
Reference
-
Gérard, P.; et al. (2007). Bacteroides sp. strain D8, the first cholesterol-reducing bacterium isolated from human feces. Applied and environmental microbiology. 73(18), 5742-5749.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
